318 related articles for article (PubMed ID: 27158050)
1. The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.
Ali AM; DiPersio JF; Schroeder MA
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1552-1564. PubMed ID: 27158050
[TBL] [Abstract][Full Text] [Related]
2. Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation.
Shin J; Dan K; Han D; Kim JW; Kim KK; Koh Y; Shin DY; Hong J; Yoon SS; Park S; Song SH; Kim I
Blood Cells Mol Dis; 2019 Feb; 74():5-12. PubMed ID: 30344086
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Predicting Acute Graft-Versus-Host Disease Using Machine Learning and Longitudinal Vital Sign Data From Electronic Health Records.
Tang S; Chappell GT; Mazzoli A; Tewari M; Choi SW; Wiens J
JCO Clin Cancer Inform; 2020 Feb; 4():128-135. PubMed ID: 32083957
[TBL] [Abstract][Full Text] [Related]
5. [Advances of Diagnostic Biomarkers on Acute Graft Versus Host Disease -Review].
Wang FY; Gao CJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):281-285. PubMed ID: 28245417
[TBL] [Abstract][Full Text] [Related]
6. Pretransplant β2-Microglobulin Is Associated with the Risk of Acute Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant.
Costa-Lima C; Miranda ECM; Colella MP; Aranha FJP; de Souza CA; Vigorito AC; De Paula EV
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1329-1332. PubMed ID: 27044906
[TBL] [Abstract][Full Text] [Related]
7. Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation.
Gimondi S; Dugo M; Vendramin A; Bermema A; Biancon G; Cavané A; Corradini P; Carniti C
Exp Hematol; 2016 Jul; 44(7):624-634.e1. PubMed ID: 27013207
[TBL] [Abstract][Full Text] [Related]
8. Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning.
Rashidi A; DiPersio JF; Westervelt P; Abboud CN; Schroeder MA; Cashen AF; Pusic I; Romee R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1137-1141. PubMed ID: 26988741
[TBL] [Abstract][Full Text] [Related]
9. Peripheral Blood CD38 Bright CD8+ Effector Memory T Cells Predict Acute Graft-versus-Host Disease.
Khandelwal P; Lane A; Chaturvedi V; Owsley E; Davies SM; Marmer D; Filipovich AH; Jordan MB; Marsh RA
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1215-22. PubMed ID: 25881755
[TBL] [Abstract][Full Text] [Related]
10. Composite biomarker panel for prediction of severity and diagnosis of acute GVHD with T-cell-depleted allogeneic stem cell transplants-single centre pilot study.
Min SS; Mehra V; Clay J; Cross GF; Douiri A; Dew T; Basu TN; Potter V; Ceesay MM; Pagliuca A; Sherwood RA; Vincent RP
J Clin Pathol; 2017 Oct; 70(10):886-890. PubMed ID: 28450387
[TBL] [Abstract][Full Text] [Related]
11. Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation.
Doehn JM; Winkler A; Kuzmina Z; Hladik A; Greinix H; Knapp S; Robak O
Exp Hematol; 2016 Oct; 44(10):917-23. PubMed ID: 27403536
[TBL] [Abstract][Full Text] [Related]
12. Graft-vs-host disease following allogeneic hematopoietic cell transplantation.
Pidala J
Cancer Control; 2011 Oct; 18(4):268-76. PubMed ID: 21976245
[TBL] [Abstract][Full Text] [Related]
13. Potential biomarkers for early detection of acute graft-versus-host disease.
Lochmanová G; Jedličková L; Potěšil D; Tomancová A; Verner J; Pospíšilová S; Doubek M; Mayer J; Zdráhal Z
Proteomics Clin Appl; 2012 Aug; 6(7-8):351-63. PubMed ID: 22927351
[TBL] [Abstract][Full Text] [Related]
14. Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.
Presland RB
Expert Rev Proteomics; 2017 Nov; 14(11):997-1006. PubMed ID: 28974115
[TBL] [Abstract][Full Text] [Related]
15. Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity.
Johnston L
Best Pract Res Clin Haematol; 2008 Jun; 21(2):177-92. PubMed ID: 18503985
[TBL] [Abstract][Full Text] [Related]
16. Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation.
Arai Y; Kondo T; Fuse K; Shibasaki Y; Masuko M; Sugita J; Teshima T; Uchida N; Fukuda T; Kakihana K; Ozawa Y; Eto T; Tanaka M; Ikegame K; Mori T; Iwato K; Ichinohe T; Kanda Y; Atsuta Y
Blood Adv; 2019 Nov; 3(22):3626-3634. PubMed ID: 31751471
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response.
Calkoen FG; Jol-van der Zijde CM; Mearin ML; Schweizer JJ; Jansen-Hoogendijk AM; Roelofs H; van Halteren AG; Egeler RM; van Tol MJ; Ball LM
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1590-9. PubMed ID: 23994245
[TBL] [Abstract][Full Text] [Related]
18. Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation.
Weissinger EM; Metzger J; Dobbelstein C; Wolff D; Schleuning M; Kuzmina Z; Greinix H; Dickinson AM; Mullen W; Kreipe H; Hamwi I; Morgan M; Krons A; Tchebotarenko I; Ihlenburg-Schwarz D; Dammann E; Collin M; Ehrlich S; Diedrich H; Stadler M; Eder M; Holler E; Mischak H; Krauter J; Ganser A
Leukemia; 2014 Apr; 28(4):842-52. PubMed ID: 23842427
[TBL] [Abstract][Full Text] [Related]
19. Citrulline and Monocyte-Derived Macrophage Reactivity before Conditioning Predict Acute Graft-versus-Host Disease.
Hueso T; Coiteux V; Joncquel Chevalier Curt M; Labreuche J; Jouault T; Yakoub-Agha I; Seguy D
Biol Blood Marrow Transplant; 2017 Jun; 23(6):913-921. PubMed ID: 28263922
[TBL] [Abstract][Full Text] [Related]
20. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
